Why FTLF Stock dropped -4.70% Today — RQD Quant Desk Flash
FitLife Brands Inc. (FTLF) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is FTLF stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, FitLife Brands Inc. (NASDAQ: FTLF) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $7.91 (-4.70% 1D, market cap $74.3M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 16/20. Across 1016 tracked Health Care issuers, FTLF ranks #417 in composite RQD confidence.
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does FTLF compare to ISPR and BTMD in the Health Care sector?
▼
Within the Health Care sector (Medicinal Chemicals and Botanical Products), FTLF carries a Roarable D (45/100 RQD), trailing P/E of 11.7x, gross margin of 43.1%, and ROIC of 5.4%. By comparison, ISPR (Ispire Technology Inc.) holds a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $79.1M) and BTMD (Biote Corp. (Class A)) posts a D grade (50/100 RQD, P/E N/A, ROIC 85.0%, cap $42.0M). Among the 5-stock peer group, NAGE leads on earnings multiple (11.4x) while BTMD leads on capital efficiency (85.0% ROIC).
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for FTLF?
▼
Per FTLF's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001374328), FitLife Brands Inc. generated $15.9M in revenue (-75.3% YoY), $6.3M in net income, and $7.4M in free cash flow against $106.3M in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC Form 4 / 13F Thermometer: 80% Net Buy • Cannibal Buyback (-2.36% YoY Shares)
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 31.7 (OVERSOLD (<32))
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
⚔️ Adversarial Opposing Case: What Could Spark a FTLF Turnaround Squeeze
While FTLF currently carries a cautious 45/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Company leadership has skin in the game with net positive insider conviction.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($9.11) and Max Pain ($8.31) forces dealer call-delta covering toward $20.95.
Forensic Repair Trigger: Halting share dilution (Cannibal Buyback (-2.36% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Why FTLF Stock dropped -4.70% Today — RQD Quant Desk Flash
FitLife Brands Inc. (FTLF) dropped -4.70% to $7.91, trading at 2% of its 52-week range ($7.66 – $19.95). Stretched risk/reward at 12x P/E (5% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($7.66 – $19.95) with RSI-14 at 31.7 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±10.2% around $7.91 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 43.1% gross margin and $7.4M annual free cash flow.
FitLife Brands (NASDAQ:FTLF) outlined its strategy to grow a portfolio of nutritional supplement and wellness brands through acquisitions, e-commerce sales and operational improvements, while acknowledging recent organic
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring FTLF)
- ✓Walkthrough of FTLF's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
FTLF Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on FTLF today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for FTLF. Explore sector supply chains on /butterfly.
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (FTLF)
1. Head-to-Head Health Care Peer Comparison (FTLF vs. ISPR, BTMD, MDWD, NAGE)
Industry: Medicinal Chemicals and Botanical Products (24 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, FitLife Brands Inc. (FTLF) ranks #417 by composite RQD confidence (45/100, grade D) and #697 by equity capitalization ($74.3M). Within this direct 5-issuer industry benchmark cohort, NAGE leads on earnings valuation at 11.4x trailing P/E, while BTMD leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. NAGE currently holds the highest overall quantitative score in the immediate peer group at 57/100 (D+) compared with FTLF at 45/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| FTLF
ACTIVE
FitLife Brands Inc. | D | 45/100 | 11.7x | 43.1% | 5.4% | -4.70% | $74.3M | Benchmark Subject |
| ISPR Ispire Technology Inc. | E | 24/100 | — | 17.8% | -35.0% | -1.44% | $79.1M | /ispr-vs-ftlf → |
| BTMD Biote Corp. (Class A) | D | 50/100 | — | — | 85.0% | +1.74% | $42.0M | /btmd-vs-ftlf → |
| MDWD MediWound Ltd. | D | 51/100 | — | — | — | +2.21% | $178.9M | /mdwd-vs-ftlf → |
| NAGE Niagen Bioscience Inc. | D+ | 57/100 | 11.4x | 64.3% | 16.8% | -1.57% | $197.8M | /nage-vs-ftlf → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001374328In its most recent audited fiscal period (FY2025, filed 2025-12-31), FitLife Brands Inc. (FTLF) reported GAAP revenue of $15.9M (-75.3% vs. FY2024 revenue of $64.5M ) , GAAP net income of $6.3M, operating cash flow of $7.4M, and free cash flow of $7.4M (-22.9% YoY). On the balance sheet, FTLF closed FY2025 with $106.3M in total assets against $0 in total debt (Altman Z-Score: 1.24, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $15.9M | $6.3M | $7.4M | $7.4M | $106.3M | — |
| FY2024 (FY) | 2024-12-31 | $64.5M | $9.0M | $9.6M | $9.6M | $58.5M | $8.6M |
| FY2023 (FY) | 2023-12-31 | $0 | $5.3M | $4.2M | $4.2M | — | — |
3. FTLF Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs FTLF stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, FitLife Brands Inc. (NASDAQ: FTLF) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $7.91 (-4.70% 1D, market cap $74.3M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 16/20. Across 1016 tracked Health Care issuers, FTLF ranks #417 in composite RQD confidence.
How does FTLF compare to ISPR and BTMD in the Health Care sector?
Within the Health Care sector (Medicinal Chemicals and Botanical Products), FTLF carries a Roarable D (45/100 RQD), trailing P/E of 11.7x, gross margin of 43.1%, and ROIC of 5.4%. By comparison, ISPR (Ispire Technology Inc.) holds a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $79.1M) and BTMD (Biote Corp. (Class A)) posts a D grade (50/100 RQD, P/E N/A, ROIC 85.0%, cap $42.0M). Among the 5-stock peer group, NAGE leads on earnings multiple (11.4x) while BTMD leads on capital efficiency (85.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for FTLF?
Per FTLF's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001374328), FitLife Brands Inc. generated $15.9M in revenue (-75.3% YoY), $6.3M in net income, and $7.4M in free cash flow against $106.3M in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is FTLF trading relative to its 50-day, 200-day, and 52-week technical levels?
FTLF last traded at $7.91 (-4.70% on volume of 21,788 shares), positioning the stock -13.17% below its 50-day simple moving average ($9.11) and -28.93% below its 200-day simple moving average ($11.13). Across its 52-week range of $7.66 to $19.95, FTLF sits at the 2.0% percentile with a 14-day RSI of 31.7 (OVERSOLD (<32)) and an implied next-earnings move of ±10.2% ($7.10 to $8.72).
FTLF Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is FTLF stock moving today?
Why FTLF Stock dropped -4.70% Today — RQD Quant Desk Flash. Stretched risk/reward at 12x P/E (5% return on capital) under elevated 10-year interest-rate pressure.